ATE230795T1 - In situ modifikation und manipulation von stammzellen des zentralen nervensystems - Google Patents

In situ modifikation und manipulation von stammzellen des zentralen nervensystems

Info

Publication number
ATE230795T1
ATE230795T1 AT94931482T AT94931482T ATE230795T1 AT E230795 T1 ATE230795 T1 AT E230795T1 AT 94931482 T AT94931482 T AT 94931482T AT 94931482 T AT94931482 T AT 94931482T AT E230795 T1 ATE230795 T1 AT E230795T1
Authority
AT
Austria
Prior art keywords
cells
situ
stem cells
manipulation
nervous system
Prior art date
Application number
AT94931482T
Other languages
English (en)
Inventor
Samuel Weiss
Brent A Reynolds
Der Kooy Derek Van
Cindi Morshead
Constance Craig
Original Assignee
Neurospheres Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurospheres Holdings Ltd filed Critical Neurospheres Holdings Ltd
Application granted granted Critical
Publication of ATE230795T1 publication Critical patent/ATE230795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
AT94931482T 1993-11-09 1994-11-08 In situ modifikation und manipulation von stammzellen des zentralen nervensystems ATE230795T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14950893A 1993-11-09 1993-11-09
PCT/CA1994/000614 WO1995013364A1 (en) 1993-11-09 1994-11-08 In situ modification and manipulation of stem cells of the central nervous system

Publications (1)

Publication Number Publication Date
ATE230795T1 true ATE230795T1 (de) 2003-01-15

Family

ID=22530608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931482T ATE230795T1 (de) 1993-11-09 1994-11-08 In situ modifikation und manipulation von stammzellen des zentralen nervensystems

Country Status (12)

Country Link
EP (1) EP0728194B1 (de)
JP (1) JP3952508B2 (de)
CN (1) CN1141058A (de)
AT (1) ATE230795T1 (de)
AU (1) AU697894B2 (de)
CA (1) CA2175992C (de)
DE (1) DE69431993T2 (de)
DK (1) DK0728194T3 (de)
ES (1) ES2189807T3 (de)
FI (1) FI120455B (de)
NO (1) NO317724B1 (de)
WO (1) WO1995013364A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI971956L (fi) * 1994-11-14 1997-07-04 Neurospheres Holdings Ltd Hermosolujen lisääntymisen säännöstely
WO1997035605A1 (en) * 1996-03-26 1997-10-02 Neurospheres Holdings Ltd. Manipulation of mitotically active cells of the hippocampal region of the brain
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
US6787355B1 (en) 1996-08-26 2004-09-07 Mcgill University Multipotent neural stem cells from peripheral tissues and uses thereof
CA2216439A1 (en) * 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
JP2001504123A (ja) * 1996-11-15 2001-03-27 ニューロスフェレス ホールディングス リミテッド Ｃｎｓ障害に対して保護するための成長因子を用いた予備治療
US20020123143A1 (en) 1997-08-22 2002-09-05 Jean Toma Multipotent stem cells from peripheral tissues and uses thereof
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6541247B1 (en) 1998-06-25 2003-04-01 Neuronova Ab Method of isolating ependymal neural stem cells
SE9802264D0 (sv) 1998-06-25 1998-06-25 Neuronova Ab A method of isolating cells
US7544509B2 (en) 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
AU3499801A (en) 2000-02-11 2001-08-20 Schepens Eye Res Inst Isolation and transplantation of retinal stem cells
WO2002069975A1 (en) * 2001-03-02 2002-09-12 Stem Cell Therapeutics Inc. Use of estrogen to induce neural stem cell increase
EP1423509A2 (de) 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differenzierung von neuralen stammzellen und therapeutische anwendung
EP1430114B1 (de) 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
WO2003060082A2 (en) 2002-01-14 2003-07-24 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
EP2095823A1 (de) * 2002-07-30 2009-09-02 Stem Cell Therapeutics Inc. Oligodendrozytenherstellung aus multipotenten neuralen Stammzellen
US20040185429A1 (en) 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
ES2392282T3 (es) 2004-02-13 2012-12-07 Stem Cell Therapeutics Corp. Uso de la hormona luteinizante (LH) y de la gonadotropina coriónica (hCG) para la proliferación de células precursoras neurales y la neurogénesis
WO2006055685A2 (en) 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
WO2007106986A1 (en) 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
JPWO2008093827A1 (ja) * 2007-02-01 2010-05-20 財団法人大阪産業振興機構 中枢神経障害治療剤及び中枢神経障害の治療方法
JP2009278873A (ja) * 2008-05-19 2009-12-03 Japan Health Science Foundation 培地および培養方法
SG187226A1 (en) 2010-07-28 2013-03-28 Neuralstem Inc Methods for treating and/or reversing neurodegenerative diseases and/or disorders
JP6468843B2 (ja) 2012-02-17 2019-02-13 ザ スキーペンズ アイ リサーチ インスティチュート ヒト網膜前駆細胞の表現型プロファイル
WO2014157047A1 (ja) * 2013-03-27 2014-10-02 千葉県 神経変性疾患治療剤
CN107148275A (zh) 2014-10-20 2017-09-08 神经干细胞公司 包含编码生长因子的外源多核苷酸的稳定的神经干细胞及其使用方法
CN113564123B (zh) 2014-10-24 2024-11-15 住友制药株式会社 神经组织的制备方法
JP6995314B2 (ja) * 2016-04-22 2022-02-21 大日本住友製薬株式会社 網膜組織の製造法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
WO1994016718A1 (en) * 1991-07-08 1994-08-04 Neurospheres Ltd. Genetic modification of neural stem cells
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation

Also Published As

Publication number Publication date
FI961855A0 (fi) 1996-04-30
DE69431993D1 (de) 2003-02-13
AU8056194A (en) 1995-05-29
FI120455B (fi) 2009-10-30
EP0728194A1 (de) 1996-08-28
JP3952508B2 (ja) 2007-08-01
EP0728194B1 (de) 2003-01-08
NO961859D0 (no) 1996-05-08
DK0728194T3 (da) 2003-04-22
FI961855L (fi) 1996-06-04
NO317724B1 (no) 2004-12-13
WO1995013364A1 (en) 1995-05-18
CA2175992C (en) 2008-04-01
JPH09507747A (ja) 1997-08-12
DE69431993T2 (de) 2003-11-27
NO961859L (no) 1996-07-03
AU697894B2 (en) 1998-10-22
CN1141058A (zh) 1997-01-22
CA2175992A1 (en) 1995-05-18
ES2189807T3 (es) 2003-07-16

Similar Documents

Publication Publication Date Title
DE69431993D1 (de) In situ modifikation und manipulation von stammzellen des zentralen nervensystems
IL147990A0 (en) Multipotent adult stem cells and methods for isolation
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
DK0395355T3 (da) Frigivelse af celler fra affinitetsmatricer
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
GEP20063830B (en) Nogo Receptor-Mediated Blockade of Axonal Growth
FI952797A0 (fi) D-vitamiinianalogin uusi kiteinen muoto
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DK0892849T3 (da) Fremgangsmåde til anvendelse af obese-genet og dets genprodukt til stimulering af hæmatopoietisk udvikling
WO2000066730A3 (en) Laminin 2 and methods for its use
ATE345496T1 (de) In-vitro-musters für zns - funktion und dysfunktion
ATE154245T1 (de) Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen
ATE473273T1 (de) Angereicherte zellpopulationen des zentralen nervensystems
ATE231727T1 (de) Zusammensetzung für verbesserung der pankreasfunktion
DE69504646D1 (de) Herstellung und stabilisierung von zellsuspensionen
DE3572368D1 (en) Microorganisms of the strain phanerochaete chrysosporium and their use
PT914419E (pt) Ratinhos transgenicos capazes de expressar o factor de inibicao de leucemia
EP0724644A4 (de) Für die untereinheiten der 1,3-beta-d-glucansynthase kodierende dna
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
GB1292701A (en) Improvements in or relating to the thermal hydrodealkylation of alkylbenzene compounds
DE69737101D1 (de) Zusammensetzungen zur gentransfer in das zentrale nervensystem
IS1986B (is) Notkun CD137 til að stuðla að fjölgun jaðar-einkjörnunga
DE69908288D1 (de) Verfahren zur Herstellung von UCN-01

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0728194

Country of ref document: EP